HER2-Low Breast Cancer Treatment Shows Major Progression-Free Survival Benefit
Phase 3 trial results from ESMO 2026 show that trastuzumab rezetecan significantly extended progression-free survival compared to chemotherapy in patients with HER2-low breast cancer. The improvement more than doubled PFS, positioning the drug as a strong contender in this subtype’s treatment landscape. Its performance raises important questions about how it may fit alongside existing therapies like T-DXd.
A Phase 3 clinical trial presented at ESMO 2026 demonstrated that trastuzumab rezetecan significantly improved progression-free survival (PFS) in patients with HER2-low breast cancer compared to standard chemotherapy. The results showed more than a doubling of PFS, marking a substantial advancement in treating this specific breast cancer subtype. While exact numerical values for PFS duration are not included in the summary, the magnitude of improvement positions trastuzumab rezetecan as a leading therapeutic option within the HER2-low category. This development follows years of research into targeted therapies for breast cancers that do not overexpress HER2 but still exhibit low-level expression, a group historically underserved by HER2-targeted treatments.
Prior to this trial, treatment for HER2-low breast cancer relied primarily on chemotherapy, with limited targeted options. The approval and use of trastuzumab deruxtecan (T-DXd) had already begun shifting the landscape by demonstrating efficacy in HER2-low disease, raising expectations for even better outcomes. Trastuzumab rezetecan’s success now introduces a new benchmark, prompting questions about how it may integrate with or potentially displace T-DXd in clinical guidelines. The trial’s findings involve patients with HER2-low breast cancer, though the specific patient population, trial duration, and statistical significance are not detailed here.
The pharmaceutical company developing trastuzumab rezetecan is not named
This breakthrough could significantly impact patients with HER2-low breast cancer, a group previously overlooked by targeted therapies. If trastuzumab rezetecan is adopted widely, it may improve long-term outcomes and reduce reliance on chemotherapy’s side effects. The treatment shift may also influence clinical trial design for other subtypes, encouraging more precision medicine approaches. Market-wise, this could challenge the dominance of T-DXd in the HER2-low space, affecting drug pricing and reimbursement strategies across healthcare systems. A comparable precedent is the introduction of trastuzumab for HER2-positive breast cancer, which revolutionized treatment and set a model for targeted therapy development. However, unlike that case, where the target was clearly overexpressed, HER2-low disease presents a more nuanced biological challenge, making this advancement particularly notable. What remains uncertain is whether trastuzumab rezetecan will achieve similar widespread adopt